Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31715177 | 0.86 | ALDH1A1 (0.43) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL12429197 | 0.86 | TEAD2 (0.45) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL31352252 | 0.85 | ADORA3 (0.57) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL15884432 | 0.84 | TEAD2 (0.48) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL20098732 | 0.84 | KDM4E (0.45) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL31714773 | 0.84 | KDM4E (0.48) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL3809702 | 0.84 | KDM4E (0.42) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL31714887 | 0.84 | TEAD2 (0.43) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D | |
| SCHEMBL23273647 | 0.83 | L3MBTL1 (0.47) | ALDH1A1MEN1KMT2AHSD17B10TSHR | |
| SCHEMBL645045 | 0.83 | ADORA3 (0.54) | ALDH1A1MEN1KMT2AHSD17B10CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-3324977-B1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2020-07-16 | — | — | US | disclosed |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | disclosed |
| EP-1966150-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073297-A1 | PYRAZOLES FOR THE TREATMENT OF GERD AND IBS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| EP-1646628-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Novartis AG (CH) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005421-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865215-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885MEN1 3463/4885KMT2A 1493/4885 |
| US-20090062365-A1 | Pyrazoles for the Treatment of GERD and IBS | GRPR, GABRB3, GABRB1 | ALDH1A1 1412/4885MEN1 4453/4885KMT2A 3841/4885 |
| US-10881666-B2 | Combination pharmaceutical agents as RSV inhibitors | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885MEN1 3503/4885KMT2A 3794/4885 |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | PPARG, PPARA, PPARD | ALDH1A1 1496/4885MEN1 4484/4885KMT2A 2246/4885 |
| US-10570153-B2 | Benzodiazepine derivatives as RSV inhibitors | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885MEN1 3463/4885KMT2A 1493/4885 |
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | ALDH1A1 3689/4885MEN1 2341/4885KMT2A 610/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | ALDH1A1 3515/4885MEN1 4238/4885KMT2A 4296/4885 |
| US-20200223867-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | ALDH1A1 621/4885MEN1 3463/4885KMT2A 1493/4885 |
| US-20190192535-A1 | COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS | SERPINB1, FURIN, HIF1AN | ALDH1A1 3562/4885MEN1 3503/4885KMT2A 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.